A phase Ib study of AZD5462 on top of dapagliflozin in participants with heart failure and moderate renal impairment - AURORA

Study identifier:D9090C00007

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:2024-513142-11-00

Will Be Recruiting

Official Title

Phase Ib Randomised, Placebo-controlled, Double-blind, Multicentre Study to Assess the Effects and Safety of AZD5462 on top of Dapagliflozin in Participants with Heart Failure and Moderate Renal Impairment

Medical condition

Renal Impairment

Phase

Phase 1

Healthy volunteers

No

Study drug

AZD5462, Dapagliflozin

Sex

All

Estimated Enrollment

40

Study type

Interventional

Age

18 Years - 85 Years

Date

Study Start Date: 23 Sept 2024
Estimated Primary Completion Date: 08 Sept 2025
Estimated Study Completion Date: 08 Sept 2025

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria